BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Matsumoto S, Kawamura H, Nishikawa T, Sagihara N, Miyatani H, Mashima H. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol 2017;10:249-58. [PMID: 29026326 DOI: 10.2147/CEG.S143224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
2 Hiraoka S, Kato J, Moritou Y, Takei D, Inokuchi T, Nakarai A, Takahashi S, Harada K, Okada H, Yamamoto K. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients. BMC Gastroenterol. 2015;15:53. [PMID: 25925267 DOI: 10.1186/s12876-015-0285-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
3 Bibliography. Intracellular Calcium 2014. [DOI: 10.1002/9781118675410.biblio] [Reference Citation Analysis]
4 Pharmacology of Intracellular Ca2+. Intracellular Calcium 2014. [DOI: 10.1002/9781118675410.ch11] [Reference Citation Analysis]
5 Miyahara K, Nouso K, Saito S, Hiraoka S, Harada K, Takahashi S, Morimoto Y, Kobayashi S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Okada H, Amano M, Hirose K, Nishimura S, Yamamoto K. Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. PLoS One 2013;8:e74861. [PMID: 24116015 DOI: 10.1371/journal.pone.0074861] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]